Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine - PubMed (original) (raw)
Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine
R Wagner et al. Arch Virol. 1992.
Abstract
Antigens in a particulate conformation were shown to be highly immunogenic in mammals. For this reason, the particle forming capacity of derivatives of the HIV-1 group specific core antigen p55 gag was assayed and compared dependent on various expression systems: recombinant bacteria, vaccinia- and baculoviruses were established encoding the entire core protein p55 either in its authentic sequence or lacking the myristylation consensus signal. Moreover, p55 gag was expressed in combination with the protease (p55-PR) or with the entire polymerase (p55-pol), respectively. Budding of 100-160 nm p55 core particles, resembling immature HIV-virions, was observed in the eucaryotic expression systems only. In comparison to the vaccinia virus driven expression of p55 in mammalian cells, considerably higher yields of particulate core antigen were obtained by infection of Spodoptera frugiperda (Sf9) insect cells with the recombinant Autographa californica nuclear polyhedrosis (AcMNPV) baculovirus. Mutation of the NH2-terminal myristylation signal sequence prevented budding of the immature core particles. Expression of the HIV p55-PR gene construct by recombinant baculovirus resulted in complete processing of the p55 gag precursor molecule in this system. The introduction of an artificial frameshift near the natural frameshift site resulted in constitutive expression of the viral protease and complete processing of p55, both in Escherichia coli and in vaccinia virus infected cells. Interestingly, significant processing of p55 resembling that of HIV infected H9 cells could also be achieved in the vaccinia system by fusing the entire pol gene to the gag gene. Moreover, processing was not found to be dependent on amino-terminal myristylation of the gag procursor molecule, which is in contrast to observations with type C and type D retrovirus. However, complete processing of p55 into p24, p17, p9 and p6 abolished particle formation. Purified immature HIV-virus like particles were highly immunogenic in rabbits, leading to a strong humoral immune response after immunization. Empty immature p55 gag particles represent a noninfectious and attractive candidate for a basic vaccine component.
Similar articles
- Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY, Luo L, Wainberg MA, Li Y. Kang CY, et al. Biol Chem. 1999 Mar;380(3):353-64. doi: 10.1515/BC.1999.047. Biol Chem. 1999. PMID: 10223338 - The life-cycle of human immunodeficiency virus type 1.
Goto T, Nakai M, Ikuta K. Goto T, et al. Micron. 1998 Apr-Jun;29(2-3):123-38. doi: 10.1016/s0968-4328(98)00002-x. Micron. 1998. PMID: 9684349 Review. - Baculoviruses: high-level expression in insect cells.
Miller LK. Miller LK. Curr Opin Genet Dev. 1993 Feb;3(1):97-101. doi: 10.1016/s0959-437x(05)80348-x. Curr Opin Genet Dev. 1993. PMID: 8453280 Review.
Cited by
- Evaluation of Virus-Free Manufacture of Recombinant Proteins Using CRISPR-Mediated Gene Disruption in Baculovirus-Infected Insect Cells.
Bruder MR, Aucoin MG. Bruder MR, et al. Vaccines (Basel). 2023 Jan 19;11(2):225. doi: 10.3390/vaccines11020225. Vaccines (Basel). 2023. PMID: 36851104 Free PMC article. - Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV.
Poteet E, Lewis P, Chen C, Ho SO, Do T, Chiang S, Labranche C, Montefiori D, Fujii G, Yao Q. Poteet E, et al. Vaccine. 2016 Nov 21;34(48):5886-5894. doi: 10.1016/j.vaccine.2016.10.036. Epub 2016 Oct 27. Vaccine. 2016. PMID: 27997339 Free PMC article. - Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus.
Nam HM, Chae KS, Song YJ, Lee NH, Lee JB, Park SY, Song CS, Seo KH, Kang SM, Kim MC, Choi IS. Nam HM, et al. Arch Virol. 2013 Jun;158(6):1275-85. doi: 10.1007/s00705-013-1612-z. Epub 2013 Feb 8. Arch Virol. 2013. PMID: 23392631 Free PMC article. - Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.
Álvarez-Fernández C, Crespo Guardo A, García-Pérez J, García F, Blanco J, Escribà-García L, Gatell JM, Alcamí J, Plana M, Sánchez-Palomino S. Álvarez-Fernández C, et al. PLoS One. 2012;7(11):e48848. doi: 10.1371/journal.pone.0048848. Epub 2012 Nov 7. PLoS One. 2012. PMID: 23144996 Free PMC article. - Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media.
Lynch A, Meyers AE, Williamson AL, Rybicki EP. Lynch A, et al. Virol J. 2012 Sep 18;9:210. doi: 10.1186/1743-422X-9-210. Virol J. 2012. PMID: 22988963 Free PMC article.
References
- Nature. 1987 Jul 23-29;328(6128):345-8 - PubMed
- Nature. 1970 Aug 15;227(5259):680-5 - PubMed
- J Virol. 1988 Nov;62(11):3993-4002 - PubMed
- Nature. 1988 Dec 1;336(6198):484-7 - PubMed
- Intervirology. 1987;27(3):148-53 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials